GEMINI 1Must knowUC · Induction and maintenance
Vedolizumab as induction and maintenance therapy for ulcerative colitis
Feagan BG, et al.
N Engl J Med 2013 · PMID 23964932 (PubMed, opens in a new tab) · doi 10.1056/NEJMoa1215734 (full paper, opens in a new tab)
| Endpoint | Vedolizumab | Every 8 weeks | Every 4 weeks | Placebo | Difference |
|---|---|---|---|---|---|
| Clinical response, Week 6 · induction (primary endpoint) | 47.1% | not in this comparison | not in this comparison | 25.5% | Adjusted difference +21.7 points (95% CI 11.6–31.7); P<0.001 |
| Clinical remission, Week 52 · randomised-withdrawal maintenance (primary endpoint) | not in this comparison | 41.8% | 44.8% | 15.9% | +26.1 points (95% CI 14.9–37.2) every 8 weeks and +29.1 points (17.9–40.4) every 4 weeks vs placebo; both P<0.001 |
Every-4-week dosing added little over every 8 weeks, which became the standard interval.
Source: Feagan 2013, abstract. Differences are adjusted for stratification factors.
Structured abstract
BackgroundGut-selective blockade of lymphocyte trafficking with vedolizumab, an anti-α4β7 integrin antibody, might treat UC without systemic immunosuppression.
MethodsTwo integrated randomised, double-blind, placebo-controlled trials: 6-week induction and randomised-withdrawal maintenance to week 52. 374 patients. Primary endpoint: Induction: clinical response at week 6. Maintenance: clinical remission at week 52 (Mayo score ≤2, no subscore >1).
ResultsPrimary result. Week 6 response 47.1% vs 25.5% (adjusted difference 21.7 points, 95% CI 11.6–31.7; P<0.001). Week 52 remission 41.8% (every 8 weeks) and 44.8% (every 4 weeks) vs 15.9% with placebo (differences 26.1 points, 95% CI 14.9–37.2, and 29.1 points, 95% CI 17.9–40.4; both P<0.001).
Take-homeVedolizumab, a gut-selective anti-integrin, induces and maintains remission in UC, with every-8-week IV maintenance as the standard.
| Patients | 374 |
|---|---|
| Population | Active UC. Induction: 374 randomised (cohort 1) plus 521 given open-label vedolizumab (cohort 2). Week-6 responders from either cohort were randomised in the maintenance trial. |
| Comparison | Vedolizumab 300 mg IV at weeks 0 and 2 vs placebo; responders randomised to vedolizumab every 8 weeks, every 4 weeks, or placebo |
| Drugs | vedolizumab |
| Classes | Anti-integrin |
| Published | Feagan BG, et al. N Engl J Med 2013;369:699–710. |
Key points
- Vedolizumab blocks α4β7 integrin, so it stops lymphocytes homing to the gut only (gut-selective).
- Every-4-week dosing added little over every-8-week dosing in maintenance (44.8% vs 41.8% remission), so every 8 weeks became standard.
- The frequency of adverse events was similar with vedolizumab and placebo.
Limitations
- Randomised-withdrawal maintenance in induction responders (an enriched population).
- Induction was judged at week 6, which may understate a drug with a slower onset.
- Placebo-controlled only; comparative data came later from VARSITY.
Commentary
Why it matters. GEMINI 1 introduced a new mechanism, gut-selective anti-integrin therapy, with a safety profile attractive for older patients and those with infection concerns.
What came after. VARSITY (PMID 31553834) showed vedolizumab was superior to adalimumab for clinical remission at week 52 in moderately to severely active UC, the first head-to-head biologic trial in IBD. VISIBLE 1 (PMID 31470005) showed that, after IV induction, subcutaneous vedolizumab 108 mg every 2 weeks was superior to placebo for week-52 remission (46.2% vs 14.3%), with a rate similar to IV every 8 weeks (42.6%; not formally compared).
Canada. Vedolizumab is marketed in Canada in IV and subcutaneous forms.
Journal club
Design
Two integrated randomised, double-blind, placebo-controlled trials: 6-week induction and randomised-withdrawal maintenance to week 52. 374 patients.
Primary result. Week 6 response 47.1% vs 25.5% (adjusted difference 21.7 points, 95% CI 11.6–31.7; P<0.001). Week 52 remission 41.8% (every 8 weeks) and 44.8% (every 4 weeks) vs 15.9% with placebo (differences 26.1 points, 95% CI 14.9–37.2, and 29.1 points, 95% CI 17.9–40.4; both P<0.001).
Validity and applicability
- Randomised-withdrawal maintenance in induction responders (an enriched population).
- Induction was judged at week 6, which may understate a drug with a slower onset.
- Placebo-controlled only; comparative data came later from VARSITY.
Where it sits now
Vedolizumab, a gut-selective anti-integrin, induces and maintains remission in UC, with every-8-week IV maintenance as the standard.
- ASTRO (2026): Guselkumab can be started with subcutaneous 400 mg injections instead of IV infusions, with clear benefit over placebo by week 12.
- RELIEVE UCCD (UC) (2026): Duvakitug, an anti-TL1A antibody, showed a dose-related remission signal in UC in phase 2b; phase 3 trials will decide its place.
- QUASAR (2025): Guselkumab induces and maintains remission in UC, and the follow-up ASTRO trial showed induction can be given subcutaneously.
- TUSCANY-2 (2025): Afimkibart missed its phase 2b primary endpoint (total Mayo remission), although remission by the modified Mayo score favoured it; anti-TL1A therapy still needs phase 3 proof.
Questions for discussion
- Maintenance re-randomised week-6 responders. How does this enriched design affect maintenance rates compared with a treat-through trial?
- Induction was judged at week 6. Is that a fair test for a drug with a slower onset?
- Every-4-week dosing added little in maintenance. When, if ever, would you shorten the interval?